Cargando…

Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma

BACKGROUND: The third-generation epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have shown significant therapeutic effects on patients with non-small cell lung carcinoma (NSCLC) who carry active EGFR mutations, as well as those who have developed acquired resistance to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Yuting, Qian, Xixi, Zhao, Li, Li, Nan, Wu, Shengjie, Chen, Baoan, Sun, Tong, Wang, Xuerong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050891/ https://www.ncbi.nlm.nih.gov/pubmed/33858423 http://dx.doi.org/10.1186/s12935-021-01914-y

Ejemplares similares

Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
por: Sun, Hui-Yan, et al.
Publicado: (2022)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
por: Wu, Dayu, et al.
Publicado: (2022)

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members
por: Malik, Nazma, et al.
Publicado: (2015)

Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis
por: Fu, Rong, et al.
Publicado: (2022)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
por: Trivedi, Archit, et al.
Publicado: (2020)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer
por: Chetry, Mandika, et al.
Publicado: (2022)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins
por: Chabert, Clovis, et al.
Publicado: (2017)

Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
por: Bian, Benjamin, et al.
Publicado: (2019)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation
por: Nguyen, Thi Hiep, et al.
Publicado: (2016)

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
por: Li, Xinying, et al.
Publicado: (2021)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease
por: Manni, Michelle L., et al.
Publicado: (2017)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
por: Lai, Jiacheng, et al.
Publicado: (2021)

Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors
por: Chen, Siao, et al.
Publicado: (2021)

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
por: Shi, Xiyao, et al.
Publicado: (2022)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
por: Martella, Noemi, et al.
Publicado: (2023)

Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins
por: Ajgaonkar, Sandeep, et al.
Publicado: (2023)

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
por: Wadhwa, Elizabeth, et al.
Publicado: (2016)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors
por: Kitazawa, Satoshi, et al.
Publicado: (2017)

Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors
por: Groves, Andrew, et al.
Publicado: (2022)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
por: Wong, C, et al.
Publicado: (2014)

Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
por: De Riick, Jan, et al.
Publicado: (2013)

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function
por: Pinz, Sophia, et al.
Publicado: (2015)

77232 The role of the bromodomain and extra-terminal motif (BET) family of proteins in head and neck cancer tumorigenic phenotype
por: Sample, Reilly A., et al.
Publicado: (2021)

Antiproliferative activity and apoptosis-inducing mechanism of constituents from Toona sinensis on human cancer cells
por: Yang, Shengjie, et al.
Publicado: (2013)

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
por: Sun, Yanli, et al.
Publicado: (2021)

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
por: Zhou, Bing, et al.
Publicado: (2017)

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease
por: Snyder, Katiri J., et al.
Publicado: (2021)

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
por: Xia, Leiming, et al.
Publicado: (2021)

miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1
por: Wang, Zhihui, et al.
Publicado: (2019)

miR-363 suppresses the proliferation, migration and invasion of clear cell renal cell carcinoma by downregulating S1PR1
por: Xie, Yongpeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iqileuubn1b6thv7q8tbb0qi52